T&R BIOFAB CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,760 KRW | +0.30% |
|
+1.50% | -24.30% |
| Sales 2022 | 5.75B 4.21M | Sales 2023 | 5.2B 3.8M | Capitalization | 192B 141M |
|---|---|---|---|---|---|
| Net income 2022 | -10.34B -7.56M | Net income 2023 | -13.42B -9.81M | EV / Sales 2022 | 38.8 x |
| Net cash position 2022 | 19.35B 14.14M | Net cash position 2023 | 5.73B 4.19M | EV / Sales 2023 | 35.9 x |
| P/E ratio 2022 |
-23.1
x | P/E ratio 2023 |
-14.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.77% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.30% | ||
| 1 week | +1.50% | ||
| Current month | -3.15% | ||
| 1 month | -18.36% | ||
| 3 months | +2.42% | ||
| 6 months | -14.43% | ||
| Current year | -24.30% |
1 week
6 650.00
7 480.00
1 month
6 550.008 720.00
Current year
6 280.0011 100.00
1 year
6 280.0014 200.00
3 years
6 280.0045 500.00
5 years
3 250.0045 500.00
10 years
3 250.0045 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Won-Soo Yoon
FOU | Founder | 54 | - |
Young-Pil Kim
DFI | Director of Finance/CFO | 51 | - |
Jin-Hyung Shin
CTO | Chief Tech/Sci/R&D Officer | 39 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Won-Soo Yoon
FOU | Founder | 54 | - |
Jin-Hyung Shin
CTO | Chief Tech/Sci/R&D Officer | 39 | - |
Song-Wan Jin
BRD | Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 6,760 | +0.30% | 14 632 |
| 24-06-04 | 6,740 | -1.17% | 28,254 |
| 24-06-03 | 6,820 | -2.29% | 67,720 |
| 24-05-31 | 6,980 | +3.71% | 291,569 |
| 24-05-30 | 6,730 | -0.15% | 29,670 |
End-of-day quote Korea S.E., June 04, 2024
More quotes
T&R Biofab Co., Ltd. is a Korea-based company mainly engaged in the production and sale of bioresorbable scaffolds. The bioresorbable scaffolds are sold under the name of T&R mesh and T&R Dental Mesh. In addition, the Company is involved in the production and sale of three Dimensions (3D) biodegradable polymer printing system, bioinks, 3D organoid and 3D cell therapies, among others. The bioinks are sold under the name of deCelluid. The Company distributes its products within the domestic market and to overseas markets.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -24.30% | 106M | |
| -4.68% | 11.09B | |
| -2.30% | 8.56B | |
| +44.31% | 5.62B | |
| -25.51% | 4.41B | |
| +7.95% | 3.41B | |
| -14.17% | 2.6B | |
| -12.74% | 2.07B | |
| -13.26% | 1.92B | |
| -28.92% | 1.63B |
- Stock Market
- Equities
- A246710 Stock
